Answers are grounded in this paper and cite their sources.
The immunosuppressive microenvironment of solid tumors limits the efficacy of immunotherapy, while the neogenesis of tertiary lymphoid structures within tumors is critical for durable antitumor immunity. However, TLS formation is hindered by both metabolic barriers such as macrophage polarization and B cell metabolic imbalance and physical barriers such as the dense stroma produced by cancer-associated fibroblasts. This review describes biomimetic nanovaccines that remodel metabolic crosstalk between macrophages and B cells through a spatiotemporal cascade strategy. Targeted delivery enables systemic metabolic reprogramming to enhance the metabolic fitness of peripheral B cells. A microenvironment-responsive nanoplatform reverses macrophage phenotype and metabolism, relieves cholesterol-mediated metabolic checkpoints, and restores lymphoid tissue inducer-like functions. The nanosystem delivers key factors such as LIGHT to induce high endothelial venule neogenesis and dismantle the stromal barrier, thereby achieving spatial reconstruction and maturation of TLS. This strategy offers a novel approach to overcoming immunotherapy resistance in solid tumors and provides theoretical guidance for the design of next-generation smart nanovaccines. In this context, the vaccine function of these platforms is defined by their capacity to couple tumor antigen capture and presentation, adjuvant signaling, antigen-specific T-cell activation, and memory formation with local microenvironmental remodeling.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: